The terminal ends of eukaryotic chromosomes, termed telomeres, progressively shorten during each round of cell division eventually leading cells into senescence. Tumor cells typically overcome this barrier to unlimited proliferation by activation of the human telomerase reverse transcriptase (hTERT) gene. In contrast, in most human somatic cells hTERT expression is tightly repressed by multiple tumor suppressors. Here, we studied the regulation of hTERT by the p53 family member p73. We show that forced expression of p73 or activation of endogenous p73 by E2F1 results in the downregulation of telomerase activity. Vice versa, siRNA-mediated knockdown of p73 induces hTERT expression. Responsiveness to p73 is conferred by Sp1 binding sites within the hTERT core promoter. In tumor cells, p73 isoforms lacking the transactivation domain (DNp73) are frequently overexpressed and believed to function as oncogenes. We show that DNp73 antagonizes the repressive effect of the proapoptotic p53 family members on hTERT expression and, in addition, induces hTERT expression in telomerase-negative cells by interfering with E2F-RB-mediated repression of the hTERT core promoter. These data provide evidence that the p73 gene functions as an important regulator of telomerase activity with implications for embryonic development, cellular differentiation and tumorigenesis.
Introduction
The nucleoprotein complexes at the terminal ends of eukaryotic chromosomes, the telomeres, are composed of arrays of G-rich sequences and telomere-binding proteins (Blackburn, 2001) . Telomeres are synthesized by telomerase, an enzyme composed of RNA and catalytic protein subunits called hTERC and human telomerase reverse transcriptase (hTERT), respectively (Nakamura and Cech, 1998) . The enzymatic activity of the telomerase holo-enzyme correlates with hTERT expression, implicating this catalytic subunit as the ratelimiting component (Nakamura and Cech, 1998) . In the absence of telomerase activity and hTERT expressiona state reported for the majority of somatic cellstelomeric DNA erodes progressively with each round of cell division and eventually leads cells into senescence or into crisis, which results in cell death (Harley et al., 1990) . In contrast, undifferentiated progenitor cells in many different self-renewing tissues express telomerase, supporting the hypothesis that differentiating cells turn off telomerase, which may contribute to limiting their replicative potential (Sharma et al., 1995) . An unlimited replicative potential is one hallmark of cancer cells (Hanahan and Weinberg, 2000) . Although some tumor cells maintain telomere length by the alternative lengthening of telomere (ALT) pathway involving recombination processes, >85% of all tumor cells rather do so by inducing telomerase activity through hTERT transcriptional upregulation . Indeed, ectopic expression of hTERT in telomerasenegative cells is sufficient to restore telomerase activity and induce the immortalization of several primary human cell types (Bodnar et al., 1998) . However, although hTERT expression alone is sufficient to immortalize for example human fibroblasts in culture, spontaneous immortalization is extremely rare. This suggests that hTERT expression is under stringent negative control and multiple tumor suppressor pathways have been shown to repress coordinately hTERT expression (Lin and Elledge, 2003) .
The TP53 gene was one of the first tumor suppressors to be identified. Independent from induction of cell cycle arrest and apoptosis in response to various types of cellular stress, p53 has been reported to repress hTERT expression (Kusumoto et al., 1999; Kanaya et al., 2000; Xu et al., 2000; Shats et al., 2004) . Mapping studies on the hTERT core promoter suggested a mechanism of hTERT repression in which p53 binds to Sp1 and renders it inaccessible to hTERT promoter activation Xu et al., 2000) . A recent study using siRNA knockdown of p53 indicated that endogenous p53 induces the cyclin-dependent kinase inhibitor p21 to repress hTERT transcription via the assembly of repressive E2F-pocket protein complexes on an atypical E2F binding site in the proximal core promoter, which has been previously shown to be occupied by transcriptionally repressive E2F-pocket protein-HDAC complexes in primary human fibroblasts (Shats et al., 2004; Won et al., 2004) .
While p53 was long considered to be unique, recently two p53-related genes were discovered (Kaghad et al., 1997; Osada et al., 1998; Yang et al., 1998) . TP73 and TP63 encode proteins with remarkable sequence homology to p53, suggesting that they are also involved in the regulation of cell growth and apoptosis. Indeed, in experimental systems, p73 showed many p53-like properties: it could bind to p53 DNA binding sites, transactivate p53-responsive genes and induce cell cycle arrest or apoptosis (Jost et al., 1997; Kaghad et al., 1997) . However, despite an extensive search tumor-associated mutations of p73 were rarely identified (Stiewe and Pu¨tzer, 2002) . Instead of mutational inactivation, overexpression of p73 has been reported for a wide variety of tumor entities and in some cases even correlated with an advanced tumor stage or poor prognostic parameters (Tannapfel et al., 1999; Stiewe and Pu¨tzer, 2002) . In contrast to mice lacking p53, p73-negative mice exhibit severe developmental defects, including hydrocephalus, hippocampal dysgenesis, chronic infections and inflammation, and abnormalities in the pheromone sensory pathway . This phenotype indicates that p73 plays a fundamental role in various developmental processes and it has been reported that p73 expression is triggered along neuronal, myogenic and hematopoietic differentiation (De Laurenzi et al., 2000; Fontemaggi et al., 2001) .
The TP73 gene encodes a complex number of isoforms that arise from alternative splicing and the use of different promoters. The different isoforms can be functionally grouped into two classes: the transactivation-competent TAp73 and the transactivation-defective, N-terminally truncated DNp73 (or DTAp73) proteins (Stiewe et al., 2002a) . Whereas the proapoptotic TAp73 acts p53-like, DNp73 functions as a p53 family antagonist, which is expressed at elevated levels in several tumor types (Stiewe et al., 2002b) . Ectopic expression of DNp73 transforms NIH3T3 cells to tumorigenicity and facilitates immortalization of primary murine embryo fibroblasts (Stiewe et al., 2002b; Petrenko et al., 2003) . The tumor-promoting activity of DNp73 can be attributed to its dominant-negative function towards p53 and the other proapoptotic p53 family members (Stiewe et al., 2002a; Petrenko et al., 2003) . In addition, DNp73 targets the retinoblastoma (RB) pathway independent of its dominant-negative activity by inducing hyperphosphorylation of the RB protein .
As differentiation is closely linked to repression of telomerase activity and p73 plays a fundamental role in embryonic development and cellular differentiation, we sought to investigate a possible role for p73 as a regulator of telomerase expression. In this study, we show that TAp73 represses hTERT transcription independent of its proapoptotic function. In contrast, DNp73 induces hTERT transcription and functionally antagonizes the repressive function of the proapoptotic p53 family proteins. In summary, our studies demonstrate an important role for p73 as a regulator of hTERT transcription with implications for embryonic development, cellular differentiation and tumor biology.
Results

Repression of telomerase activity by p73
To analyse the influence of p73 expression on telomerase activity, we infected p53-negative and telomerasepositive H1299 cells with recombinant adenoviruses for the two major TAp73 isoforms, TAp73a and TAp73b (Figure 1a and b) . Telomerase activity was quantified by the telomeric repeat amplification protocol (TRAP) adapted to qPCR (Wege et al., 2003) . A timecourse analysis revealed a significant repression of telomerase activity as early as 24 h following infection with further reduction to less than 20% after 48 h ( Figure 1a ). H1299 cells infected with the control GFP adenovirus showed only slight alterations of telomerase activity. Since the activity of the telomerase holoenzyme is most commonly regulated on the level of hTERT transcription, we next measured hTERT mRNA levels by qRT-PCR. Again both TAp73a and TAp73b induced a significant reduction in the level of hTERT transcripts whereas expression of the p73 target gene p21 CDKN1A increased (Figure 1c ). The extent of hTERT repression correlated well with the transactivation of p21 suggesting that repression and transactivation might be mechanistically coupled. To analyse if p73 regulates hTERT mRNA levels by modulating hTERT promoter activity we performed reporter assays using a luciferase expression plasmid driven by the hTERT core promoter. Albeit to varying extent, the four major TAp73 isoforms a, b, g, and d all repressed the hTERT core promoter, with TAp73b and TAp73d having the strongest repression potential (Figure 1d ). Similar effects of TAp73 expression on hTERT promoter activity were obtained in several other cell lines such as U2OS (Figure 8c ) and HCT116 ( Figure 5c ).
Like p53, the transactivation-competent TAp73 isoforms are potent inducers of apoptosis in H1299 cells. To rule out the possibility that repression of telomerase activity is a consequence of apoptosis induction, we inhibited apoptosis by stable overexpression of the antiapoptotic bcl-2 protein (Figure 2a ). Following infection with AdGFP-TAp73b fluorescence microscopy and flow cytometry revealed significant induction of apoptosis in parental H1299 cells but not in the bcl-2-expressing derivative cells (Figure 2b and c) . Importantly, repression of hTERT mRNA was observed following activation of TAp73b irrespective of the bcl-2 status of the cells (Figure 2c ), indicating that repression of telomerase by p73 is not a consequence of apoptosis induction but rather a specific effect of p73.
To investigate whether activation of the endogenous p73 in H1299 cells is sufficient to repress telomerase activity, we expressed E2F1 in H1299 cells as an ER-E2F1 fusion protein that can be activated by 4-hydroxytamoxifen . E2F1 has been previously shown by us and others to activate p73 transcription by binding to E2F binding sites in the TAp73 promoter (Irwin et al., 2000; Stiewe and Pu¨tzer, 2000) . In contrast, the DNp73 promoter is not activated by E2F1 Waltermann et al., 2003) . Activation of the ER-E2F1 fusion protein results in a significant induction of TAp73 (Figure 3a and b) accompanied by a reduction in hTERT mRNA levels ( Figure 3c ). The repression of hTERT by low levels of active E2F1 is mediated by the upregulation of p73, as it is almost completely abolished by a p73-specific short hairpin RNA (shRNA) compared to a nonsilencing control shRNA (Figure 3) . At high levels of E2F1 expression repression of hTERT transcription could not be rescued by the p73 shRNA despite efficient silencing of p73 expression (Figure 3a) . This is consistent with published data showing that ectopic expression of E2F1 can repress transcription of hTERT directly (Crowe et al., 2001) . The underlying mechanism of hTERT repression by E2F1 therefore appears to be dosedependent. Whereas high levels of E2F1 repress hTERT transcription directly, low levels of E2F1 repress hTERT via induction of TAp73.
Inhibition of TAp73 relieves hTERT repression
To further investigate whether TAp73 functions as an endogenous repressor of hTERT transcription, we reduced p73 expression by shRNAs in various cells. First, telomerase-positive H1299 cells were stably transduced with retroviral vectors expressing a p73-specific shRNA. Expression of the highly homologous p63 is not influenced by the p73 shRNA (data not shown). A nonsilencing shRNA has been used as a control for unspecific silencing effects. As shown in Figure 4a , reduction of TAp73 expression to less than 30% results in a more than two-fold induction of hTERT. A similar effect of the p73 shRNA has been observed in other telomerase-positive tumor cell lines such as p53-wild-type MCF-7 and p53-negative HL60 cells (data not shown). Furthermore, two p73-specific siRNAs targeting different regions of the p73 mRNA both significantly activated the hTERT promoter, whereas a mutated p73 siRNA resulted in hTERT activity levels comparable to a nonsilencing control siRNA (Figure 4b ).
H1299 cells are tumor cells derived from a lung adenocarcinoma that like the majority of other tumor cell lines express significant levels of telomerase. The Regulation of hTERT by p73 M Beitzinger et al effect of p73 inhibition on telomerase activity was therefore expected to be low. Some tumor cell lines, however, do not express detectable amounts of telomerase, yet maintain stable telomere lengths. Such tumor cells possess an ALT presumably based on homologous recombination events. One such cell line is the osteosarcoma-derived U2OS cell line. In these cells, hTERT expression is under stringent negative control just as in most primary somatic cells (Lin and Elledge, 2003) . As shown in Figure 4c , knock down of p73 in U2OS cells results in efficient induction of hTERT expression. A nonsilencing shRNA served as an negative control, whereas a shRNA directed against the transcriptional repressor Mad provided a positive control (Lin and Elledge, 2003) . However, we could not detect any increase in telomerase activity (data not shown), which might be related to the absence of the telomerase RNA component hTERC in these cells (Guilleret et al., 2002) . These findings indicate that the endogenous p73 acts to restrict hTERT transcription in several telomerase- 
Transactivation domain is essential for hTERT repression
To map the p73 domains responsible for hTERT repression, various p73 variants were analysed. Whereas both full-length p73 proteins TAp73a and TAp73b were able to mediate repression, a point mutation in the DNA-binding domain that compromises DNA binding (R293H) interfered with hTERT repression (Figure 5a ). Interestingly, the N-terminally deleted isoforms DNp73a and DNp73b were not only defective in hTERT repression, but even activated the promoter. These data indicate an absolute requirement for the transactivation and DNA-binding domains, that is, both of the domains shown to be essential for transactivation. This suggests that transcriptional activation and repression by p73 are functionally related. A possible explanation would be the transcriptional induction of a p73 target gene that in turn represses the hTERT promoter. It has been reported that p53-mediated repression requires induction of the target gene p21 CDKN1A (Lohr et al., 2003) . However, both TAp73a and TAp73b efficiently repressed telomerase function and hTERT promoter activity in HCT116 cells genetically engineered to lack the p21 gene ( Figure 5b and c) (Waldman et al., 1995) . Furthermore, using a fusion protein of TAp73b and a modified ligand-binding domain of the murine estrogen receptor (TAp73b-ER TAM ), we were able to induce TAp73b activity with 4-hydroxytamoxifen (4OHT) (Figure 5d ). p21 as a direct transcriptional target of TAp73b was induced by 4OHT both in the absence and presence of the protein synthesis inhibitor cycloheximide (CHX). Importantly, hTERT mRNA was reduced by 4OHT treatment independent of de novo protein synthesis, indicating that no target proteins of p73 need to be synthesized in order to repress telomerase activity. CHX alone had a modest effect on both p21 and hTERT expression, possibly due to its known effects on mRNA stability. Nevertheless, CHX did not interfere with the regulation of hTERT and p21 by TAp73b. It therefore appears unlikely that hTERT repression is only a secondary effect mediated by the transactivation of p73 target genes like p21 and suggests a repression mechanism involving a direct inhibitory function p73.
Sp1 sites within the hTERT core promoter mediate transcriptional repression by p73
The activity of the hTERT core promoter in the previous experiments followed the changes in hTERT mRNA expression (Figures 1c, d and 4a, b) , indicating that p73-regulated elements are present in this promoter region. However, we could not detect binding of p73 to the hTERT core promoter by chromatin immunoprecipitation (CHIP) when H1299 cells were infected with TAp73b-expressing adenovirus, although it could readily be detected on the promoter of the p73 target gene p21 (Figure 6b) . Much of the basal promoter activity maps to five GC-rich elements, which serve as binding sites for transcription factors of the Sp1 family . In addition, the core promoter harbors two E-boxes, which were shown to be essential for the regulation of hTERT transcription by c-Myc and Mad, and a nonconsensus E2F site, which has been shown to confer repression in primary nontransformed cells by recruitment of E2F-pocket protein-histone deacetylase complexes (Wu et al., 1999; Won et al., 2004) . 
Regulation of hTERT by p73
M Beitzinger et al If p73 does not directly bind to the core promoter, it might regulate hTERT transcription indirectly. To identify the cis-regulatory element in the hTERT promoter that confers p73 responsiveness, we analysed various hTERT core promoter constructs for repression by TAp73b (Figure 6c ). Progressive 5 0 deletions up to position À32 (with respect to the transcription start) result in decreased basal activity levels. However, these deletion constructs retain sensitivity to p73 and are repressed by TAp73b by 4-6-fold. A significant reduction in repression is seen with further 5 0 deletion down to position þ 18, which deletes both the single remaining Sp1 binding site and the atypical E2F binding site. To analyse which site is responsible for repression by p73, 
Regulation of hTERT by p73 M Beitzinger et al we used mutated full-length core promoter constructs. Whereas the promoters with mutations in the E-boxes (Myc-MT) and the E2F site (E2F-MT) are almost indistinguishable from the wild-type promoter, mutations in all five Sp1 sites (Sp1-MT) again reduced the basal promoter activity and p73 responsiveness. These promoter analyses indicate that the repressive acitivity of TAp73b on the hTERT promoter requires Sp1 binding sites and suggests that TAp73b interferes with Sp1-mediated transactivation. In line with this hypothesis, the activation of the hTERT promoter in Sp1-negative Drosophila Schneider SL2 cells was completely dependent on ectopic expression of Sp1 and was strongly reduced by the transactivating p53 family members p53, TAp73a and TAp73b (Figure 6d) . Previous studies on hTERT regulation by p53 have shown that p53 inhibits Sp1 binding to the hTERT promoter by forming a p53-Sp1 complex. Similarly, we see binding of TAp73 to recombinant GST-Sp1 but not to GST alone ( Figure 6e ). The binding region maps to the zinc-finger region of Sp1, suggesting that p73-Sp1 complex formation might compromise DNA binding of Sp1 (Figure 6f ). Consistently, CHIP revealed reduced binding of both Sp1 and Sp3 to the hTERT core promoter in vivo following TAp73b expression (Figure 6g ). These findings clearly indicate that TAp73 directly interferes with the transactivation of the hTERT core promoter by Sp1 via the formation of DNA-binding defective p73-Sp1 complexes.
Induction of hTERT expression by DNp73
The transactivation domain is lacking in the DNp73 (also termed DTAp73) isoform, which is physiologically expressed from an alternative intronic promoter or by means of alternative splicing in various tumor tissues and is believed to function as an oncogene in human cancer (Pozniak et al., 2000; Yang et al., 2000; Stiewe et al., 2002a) . DNp73 acts as a dominant-negative inhibitor of all transactivating p53 family members by formation of transactivation-defective heteromeric complexes (Stiewe et al., 2002a; Slade et al., 2004) . To investigate if DNp73 counteracts hTERT repression by the proapoptotic p53 family members, we analysed the effects of coexpressing DNp73 together with p53, TAp63g and TAp73b. The hTERT promoter was repressed by all three transactivating p53 family members to similar extent (Figure 7a ). DNp73 rescued hTERT expression in a dose-dependent manner with a stronger effect on the more closely related family members TAp63g and TAp73b than on p53, indicating that DNp73 also acts as a dominant-negative inhibitor with respect to hTERT repression. However, since H1299 cells are p53-null, antagonism of p53 function cannot explain activation of the hTERT promoter observed with DNp73 expressed alone (Figures 5a and 7a) . As H1299 cells express low levels of TAp73 and silencing TAp73 expression induces hTERT transcription, activation of the hTERT promoter by DNp73a might be mediated by inhibition of TAp73 (Figure 4a and b) . In addition, we have previously shown that DNp73 is able to activate E2F-regulated promoters and interferes with the repression function of RB by inducing its hyperphosphorylation . Since the hTERT core promoter contains a nonconsensus E2F site, that has been shown to confer repression in primary nontransformed cells by recruitment of E2F-pocket protein-histone deacetylase complexes, another possibility could be that DNp73 activates the hTERT promoter by interfering with E2F-RB-mediated repression. To distinguish these possibilities, we analysed a DNp73 mutation (L102M), which compromises the ability of DNp73 to augment E2F-mediated transactivation (Oswald and Stiewe, manuscript in preparation), while it does not interfere with its dominant-negative function (Figure 7b and c) . Both the wild-type and the mutant DNp73 inhibit p53 and TAp73b induced reporter activity. Whereas expression of wild-type DNp73a induces RB hyperphosphorylation and activates an E2F-reporter plasmid, the L102M mutant does not (Figure 7b and c) . Supporting the hypothesis that DNp73 activates the hTERT promoter via inhibition of E2F-RB repression, the wild-type DNp73 but not the L102M mutant activates the full-length hTERT core promoter or a shorter fragment of the hTERT core promoter fragment containing the nonconsensus E2F binding site (Figure 7c ).
The effect of DNp73 on E2F-dependent transcription was shown to be specific for DNp73, not conserved in DNp63 and DNp53, and independent of its dominantnegative activity . To further analyse whether activation of the hTERT promoter is due to its dominant-negative activity towards the transactivationcompetent p53 family members or due to direct inactivation of RB, we performed reporter assays to compare DNp73a, DNp63a and DNp53 on the hTERT promoter and p53-and E2F-reporter plasmids. In all assays, luciferase activities were determined 48 h following transfection. Error bars denote one standard deviation of triplicate measurements. (g) H1299 cells were infected with recombinant adenoviruses expressing DNp73a or GFP as a control for 24 h. Chromatin immunoprecipitation was performed using antibodies directed against RB. Precipitated DNA was amplified with primer pairs for the hTERT promoter. Input DNA is 1% of total chromatin.
Regulation of hTERT by p73 M Beitzinger et al
Although all DN-proteins showed a dominant-negative effect towards p53 on the p53-reporter, only DNp73a had a stimulating effect on hTERT promoter activity (Figure 7d ). This correlates with the effect on the 6 Â E2F-reporter plasmid, which was only strongly activated by DNp73a (Figure 7d ). To substantiate the role of the nonconsensus E2F binding site for regulation of hTERT transcription by DNp73, we mutated the E2F site in the context of the hTERT core promoter. Whereas the wild-type core promoter was consistently activated by DNp73, this effect was completely abrogated by a mutation in the E2F binding site (Figure 7e ). In addition, the hTERT core promoter fragment from position À32 to þ 18 containing the E2F site was sufficient to mediate activation by DNp73a (Figure 7f ). If DNp73 activates the hTERT promoter by interfering with RB function, this effect should be antagonized by overexpression of RB. Indeed, a constitutively active mutant of RB (PSM-RB), which contains mutations in most major phosphorylation sites, abrogated the effect of DNp73a (Figure 7f ). Finally, CHIP revealed a decreased binding of RB to the hTERT promoter in DNp73a-transfected H1299 cells in vivo (Figure 7g ). All these data provide evidence that DNp73 activates hTERT expression in H1299 cells by stimulating transactivation via the E2F binding site.
We further analysed activation of hTERT by DNp73 using two tetracycline-regulated H1299 cell clones expressing different amounts of DNp73a (Figure 8a ). Upon induction of DNp73a expression, hTERT mRNA levels increased about two-fold depending on the amount of DNp73a expressed (Figure 8b ). We also analysed the effect of DNp73 on hTERT expression in telomerase-negative U2OS cells. Whereas TAp73b repressed the hTERT promoter, DNp73a activated the hTERT promoter in U2OS cells similar to what we observed in H1299 cells (Figure 8c) . Furthermore, following infection of U2OS cells with DNp73a retroviruses hTERT expression increased remarkably (Figure 8d ). The extent of hTERT induction correlated with the level of DNp73a protein expressed from the different retroviruses.
Whereas most tumor cells express telomerase, normal somatic cells are mostly devoid of telomerase activity. This lack of telomerase activity is considered to be a major obstacle in the transformation of human cells. For example, primary human fibroblasts lack telomerase activity and are resistant to transformation, whereas its hTERT-transfected derivative is readily transformed to tumorigenicity by the simian virus SV40 early region and oncogenic H-rasV12 (Hahn et al., 1999) . Inactivation of tumor suppressors that repress telomerase expression (e.g. menin) or overexpression of oncogenes that activate telomerase expression (e.g. c-Myc) might therefore contribute to tumor formation in humans (Lin and Elledge, 2003) . Since DNp73 is believed to function as an oncogene in the development of human cancer, we further investigated whether DNp73 expression is able to induce telomerase expression in telomerasenegative primary human fibroblasts (Stiewe and Pu¨tzer, 2002; Moll and Slade, 2004) . As shown in Figure 8e , hTERT transcription is indeed induced in cells that stably express the DNp73a protein. Induction of hTERT by c-Myc was used as a positive control (Wu et al., 1999) .
Discussion
Our data demonstrate that p73 functions as a regulator of hTERT expression. In contrast to its family member p53, which only serves to repress hTERT transcription, regulation of hTERT by p73 is different for the various p73 isoforms that have been described so far (Kusumoto et al., 1999; Kanaya et al., 2000; Xu et al., 2000; Shats et al., 2004) . Both N-and C-terminal variability influence the way how p73 affects hTERT transcription. hTERT transcript levels were quantified in the two indicated tet-on H1299 cell clones by qRT-PCR in the presence and absence of tetracycline. hTERT mRNA levels were normalized to GAPDH expression. hTERT expression in the off-state (Àtet) was set as one.
(c) Regulation of the hTERT core promoter by TAp73b and DNp73a was analysed in U2OS cells in a luciferase assay using the p181 hTERT promoter plasmid. (d) U2OS cells were stably transduced with the indicated retroviruses expressing DNp73a under the control of the weak thymidine kinase (TK) or the stronger EF1a promoter. Activation of hTERT expression by DNp73a is shown by semiquantitative RT-PCR. (e) Primary human diploid fibroblasts were infected with the indicated DNp73a or c-Myc expressing retroviruses. Expression of hTERT, DNp73a and GAPDH was assessed by semiquantitative RT-PCR on total RNA isolated 4 days after infection.
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Whereas the TAp73 isoforms repress the hTERT promoter in correlation to their transactivation potential, the putatively oncogenic DNp73 isoforms activate hTERT expression. This is consistent with known functions of the various p73 isoforms in cellular differentiation and tumorigenesis. TAp73 expression is induced by cellular stress signals that partially overlap with activators of p53. In addition, the TAp73 promoter is activated by E2F1 and other proapoptotic genes such as adenoviral E1A and c-Myc, and during the course of cellular differentiation processes such as myogenic, hematopoietic and neuronal differentiation (De Laurenzi et al., 2000; Stiewe and Pu¨tzer, 2000; Fontemaggi et al., 2001; Zaika et al., 2001 ). Here, we have shown that induction of TAp73 expression by E2F1 triggers hTERT repression in H1299 cells. Furthermore, hTERT expression is known to be downregulated both by cellular stress and during the terminal differentiation of progenitor cells when TAp73 expression is induced, suggesting that TAp73 might also play a causal role in hTERT regulation under these conditions (Sharma et al., 1995; Xu et al., 1996) . Considering that p73 loss predisposes mice to various types of cancer (Flores et al., 2005) , it is intriguing to speculate that p73 haploinsufficiency might result in elevated levels of mTERT, thus selecting for cells that have acquired the proper genetic hits to become cancerous. In contrast to downregulation of hTERT by differentiation or proapoptotic stress signals, hTERT is typically activated in immortal cells and established tumors . We and other groups have recently demonstrated that tumor cells frequently overexpress N-terminally truncated p73 isoforms that result from abberant splicing or the use of an alternative intronic promoter (Fillippovich et al., 2001; Grob et al., 2001; Kartasheva et al., 2002; Stiewe et al., 2002a, b; Zaika et al., 2002; Pu¨tzer et al., 2003) . These DNp73 proteins act as dominant-negative inhibitors of the proapoptotic p53 family members by formation of transactivation-defective heteromeric complexes (Grob et al., 2001; Kartasheva et al., 2002; Stiewe et al., 2002a) . Such a dominant-negative function of DNp73 has also been observed in this study with respect to hTERT regulation. Although all transactivating p53 family members (p53, TAp63g and TAp73b) significantly repressed the hTERT promoter, DNp73 rescued this repression in a dose-dependent manner. In addition, DNp73 activated the hTERT promoter on its own depending on the presence of an E2F binding site in the core promoter region. Furthermore, DNp73 even activated hTERT expression in telomerase-negative cells such as U2OS tumor cells or primary human fibroblasts. However, in contrast to ectopic expression of hTERT, activation of hTERT by DNp73 was not robust enough to immortalize human fibroblasts, which might be related to the fact that primary human fibroblasts do not tolerate long-term expression of DNp73 in the absence of cooperating secondary mutations (data not shown).
Although regulation of hTERT by p73 is more complex than in the case of p53, the underlying mechanisms are similar. For p53-mediated repression of hTERT essentially two different mechanisms have been proposed. First, p53 can interact with transcription factors of the Sp1 family that account for most of the basal activity of the hTERT promoter Xu et al., 2000) . Interference with Sp1-mediated hTERT activation was also observed for TAp73b in our experiments. Mutations in all five Sp1 binding sites abolished repression of the hTERT promoter, TAp73b efficiently inhibited Sp1 activation of the hTERT promoter in Drosophila Schneider SL2 cells, and Sp1/ Sp3 binding to the promoter was lost in vivo. Furthermore, we also have indications that endogenous TAp73 represses hTERT transcription via interference with Sp1 transactivation because activation of the hTERT promoter by p73 knockdown was significantly reduced by mutations in the five Sp1 binding sites (data not shown).
The second regulatory mechanism that was proposed is based on the observation that the core promoter contains an E2F binding site allowing p53 to regulate hTERT expression via modulation of the p16-RB pathway (Shats et al., 2004; Won et al., 2004) . This E2F binding site was shown to recruit repressive E2F-RB-HDAC complexes to the hTERT core promoter in primary human fibroblasts rendering hTERT transcription susceptible to the cell cycle and to common, tumorassociated alterations in the p16-RB pathway (Won et al., 2004) . Shats et al. (2004) recently showed that p53-mediated repression of hTERT requires induction of the p53 target gene p21, which acts to direct HDACdependent repressor complexes to the hTERT promoter. As p21 is a common target gene of p53 and TAp73, it could be assumed that induction of p21 by TAp73 can contribute to hTERT repression. In fact, induction of p21 expression by TAp73b correlated with the extent of hTERT repression. Nevertheless, p21 turned out to be dispensable for repression of hTERT by TAp73. However, not only induction of p21 but also induction of other p73 target genes is not required as hTERT is efficiently repressed even in the absence of de novo protein synthesis. Therefore, interference with DNA binding of Sp1 appears to be the major repressive mechanism of p73 on the hTERT promoter.
In contrast, activation of the hTERT promoter by DNp73 appears to occur via two separate mechanisms that might operate in a cell-or tissue-specific manner. First, DNp73 can interfere with the repressive function of the transactivating p53 family member via its dominant-negative activity. Second, DNp73 can interfere with E2F-RB-mediated repression of the hTERT core promoter. In H1299 cells, transcriptional activation of hTERT by DNp73 was completely dependent on the presence of an E2F binding site in the hTERT promoter and binding of RB to this site was reduced by DNp73 in vivo. Furthermore, the analysis of DNp73 point mutants and DN-isoforms of other p53 family members revealed a striking correlation between the ability of DNp73 to regulate E2F-dependent transcription and to activate the hTERT promoter in H1299 cells. DNp73 therefore uses a novel mechanism to activate hTERT expression that has not been previously described for any other p53 family member. DNp73 can therefore utilize different nonredundant pathways to regulate hTERT expression and therefore adds another layer of complexity to the regulation of telomerase activity in cellular differentiation and tumorigenesis.
Materials and methods
Cell culture and flow cytometry H1299, 293T, U2OS and BJ cells were obtained from the ATCC, retroviral producer cells PT67 from Clontech, p21
À/À HCT116 cells were obtained from Bert Vogelstein (Johns Hopkins University, Baltimore, USA). All cell lines were maintained in Dulbecco's modified Eagle's medium (PAA) supplemented with 10% fetal calf serum, 1% penicillin G/streptomycin sulfate (PAA) and 0.4% amphotericin B (PAA). H1299 tet-on DNp73a cells were established by cotransfection of H1299 tet-on cells (kindly provided by K Vousden) with pBI-MCS-EGFP-DNp73a and pIRESpuro2. Stable cell clones were selected with 1 mg/ml puromycin (Sigma) and screened for tetracycline-regulated DNp73a expression. Drosophila Schneider SL2 cells were obtained from Guntram Suske (University of Marburg, Germany) and maintained in InsectExpress Sf9-S2 medium (PAA). For propidium iodide staining, cells were resuspended in hypotonic buffer (0.1% sodium citrate, 0.1% Triton-X, 50 mg/ml propidium iodide) and cell cycle profiles were measured directly on a FACScalibur with Cellquest software (Becton Dickinson).
RNA interference siRNAs for specific gene knockdown were synthesized by in vitro transcription with T7 RNA polymerase using the Silencert siRNA Construction Kit (Ambion). siRNAs were transfected with Lipofectamine 2000 (Invitrogen) at a final concentration of 40 nM. shRNAs were expressed from the pLVTHM vector (Wiznerowicz and Trono, 2003) . mRNA target sequences for RNA interference: nonsilencing siRNA/ shRNA -5 0 -UUC UCC GAA CGU GUC ACG U-3 0 ; p73si1 -5 0 -CCA CGA GCU CGG GAG GGA C-3 0 ; p73si1-mut -5 0 -CCA CGA GAC GGG GAG GGA C-3 0 ; p73si2 -5 0 -GCC GGG GGA AUA AUG AGG U-3 0 , p73 shRNA -5 0 -GGC CAU GCC UGU UUA CAA G-3 0 , and mad shRNA -5 0 -GUC GAC ACA CUA CGU UGA G-3 0 .
Plasmids hTERT core promoter constructs p181, p150, p100, 70, p32, p þ 18, Myc-MT, Sp1-MT, the reporter plasmids p53-Luc and 6 Â E2F-Luc, the expression plasmids for p73 isoforms, p53, TAp63g, DNp63a, DNp53, ER-E2F1 and PSM-RB have been described previously Stiewe et al., 2002a Stiewe et al., , 2003 . The E2F-MT construct and the L102M mutant of DNp73a were generated by site-directed mutagenesis using the QuikChange s Multi-Site-Directed Mutagenesis Kit (Stratagene). The hTERT(À32/ þ 18) promoter fragment was cloned as an oligonucleotide into pGL3-basic (Promega). The tamoxifen-regulatable TAp73b construct was generated by cloning a modified ligand-binding domain of the mouse estrogen receptor (ER TAM ), which binds 4-OHT but not endogenous estrogens (Littlewood et al., 1995) , into pcDNA3.1. The coding sequence of TAp73a was fused inframe to this sequence, encoding amino acids 281-599 of the receptor. Retroviral plasmids were constructed by cloning HAbcl-2 into pLPC (kindly provided by S Lowe) and DNp73a and c-Myc into pWPI (kindly provided by D Trono). For tetregulated expression of DNp73a, the DNp73a cDNA was cloned into pBI-MCS-EGFP (Yu et al., 1999) . Expression constructs for SL2 cells were generated by replacement of the Sp1 cDNA in pPAC-Sp1 with the p53, TAp73a and TAp73b cDNAs (Suske, 2000) . Plasmids for GST-Sp1 fusion proteins have been described previously (Murata et al., 1994) .
Transfections and luciferase assays Plasmid transfections for luciferase assays were performed with 1000 ng total DNA per 4 Â 10 4 cells in a 24-well plate using 2 ml JetPEI transfection reagent (Biomol). Typically, a mixture of 200 ng reporter plasmid and 200 ng expression plasmid was used. Luciferase activity was measured 48 h posttransfection using a luciferase reporter assay system (Promega). In cases of double siRNA and plasmid transfections, siRNAs were transfected first using Lipofectamine 2000 for 6 h followed by plasmid transfection with JetPEI for further 6 h. Transfection of Schneider SL2 cells was performed as described (Suske, 2000) .
Viral vectors and infections
Recombinant adenoviruses expressing GFP, TAp73a, TAp73b and DNp73a have been described (Stiewe et al., 2002a) . Infectious retroviruses for HA-bcl-2 and ER-E2F1 were produced by transient transfection of PT67 cells using 10 ml JetPEI transfection reagent (Biomol) with a combination of 2.5 mg retroviral construct and 2.5 mg pMD2G (provided by D Trono) for VSV-G pseudotyping. Retrovirus containing supernatant was collected 48-72 h after transfection and used for infection of target cells in the presence of 8 mg/ml polybrene. Infected cells were selected with 1 mg/ml puromycin. Recombinant retroviruses encoding DNp73a, c-Myc or shRNAs were produced by transient transfection of 293T cells according to standard protocols (Zufferey et al., 1997) . Briefly, subconfluent 293T cells were cotransfected with a plasmid vector, and the helper plasmids pCMV-R8.74, pMD2G and pRSV-rev by calcium phosphate precipitation. After 16 h, the medium was changed, and recombinant viruses were harvested 24-48 h later for infection of target cells. Infection efficiency was verified to be >95% by GFP fluorescence.
GST pulldown assays Full-length Sp1 or fragments of Sp1 were expressed as GST fusion proteins in Escherichia coli BL21 and purified as described previously (Murata et al., 1994) . The purity of the recombinant proteins was assessed by SDS-PAGE followed by Coomassie staining. For GST pulldown assays, TAp73a or TAp73b were in vitro translated in the presence of 35 Smethionine with the TNT s Quick Coupled Transcription/ Translation System (Promega) and incubated with GST or GST-Sp1 fusion proteins on glutathione-sepharose beads (Perbio) in GST pulldown buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 0.1 mM EDTA, 2 mM DTT, 10% glycerol, 0.1% Nonidet P-40). Following exhaustive washes, bound p73 proteins were eluted by the addition of Laemmli sample buffer and boiling and resolved by SDS-PAGE. Acrylamide gels were prepared for fluorography, dried and analysed by autoradiography.
Chromatin immunoprecipitation
The ChIP assay was essentially performed as described by Orlando et al, (1997) . Briefly, 1 Â 10 8 cells were fixed with formaldehyde (final concentration 1% (vol/vol)) in the cell culture medium for 15 min at room temperature. Glycine was added to a final concentration of 0.125 M to stop crosslinking. Fixed cells were pelleted by centrifugation and sequentially washed during rotation at room temperature for 15 min each in buffer A (10 mM Tris (pH 8.0), 10 mM EDTA, 0.5 mM EGTA, 0.25% Triton X-100) and buffer B (10 mM Tris (pH 8.0), 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA). The cells were resuspended in lysis buffer (10 mM Tris (pH 8.0), 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.1% sodium deoxycholate) and then sonicated (five times for 20 s each) to make soluble chromatin. Samples of total chromatin were taken at this point as input controls in the PCR reactions. The cell lysates were precleared by incubation with blocked protein G agarose (Upstate) and then incubated with blocked protein G agarose and antibodies (anti-Sp1 (PEP2, Santa Cruz), anti-Sp3 (D-20, Santa Cruz), anti-acetylhistone H4 (Upstate), anti-RB (G3-245, Pharmingen) or anti-p73 (ER15, Oncogene)) overnight at 41C. DNA-protein complexes were eluted from the antibodies with two incubations in elution buffer (10 mM Tris (pH 8.0), 1% SDS) at room temperature for 15 min. Crosslinks were reversed by incubation at 651C for 5 h and addition of RNase A and proteinase K. Samples were then extracted twice by phenolchloroform and precipitated overnight in the presence of 20 mg glycogen as a carrier. Resuspended DNA fragments were used for PCR amplifications with primers for the hTERT and p21 promoter.
Immunoblot Cells were lysed in RIPA buffer (50 mM Tris-Cl, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) and the total protein concentration was quantified by Bradford assay. Samples were separated by SDS-PAGE and transferred onto nitrocellulose membranes. After blocking with 10% nonfat dry milk, membranes were probed with antibodies specific for FLAG-tag (M2, Sigma), HA-tag (Y11, SantaCruz), bcl-2 (124, Dako), p73 (ER15, Oncogene), RB (1F8, SantaCruz) or b-actin (AC15, Abcam).
TRAP assay
The TRAP assay was used to determine telomerase activity. Cell lysis was performed in CHAPS buffer (10 mM Tris (pH7.5), 1 mM MgCl 2 , 1 mM EGTA, 0.1 mM PMSF, 5 mM b-ME, 0.5% CHAPS) and equal amounts of protein (2 mg) were used in each reaction. Telomerase activity was quantified by qPCR as described previously (Wege et al., 2003) .
Reverse transcription-PCR RNA was isolated using the RNeasy Kit (Qiagen) and quantified with Ribo Green (Molecular Probes). Total RNA (1 mg) was reverse transcribed with Omniscript RT (Qiagen) in a reaction volume of 20 ml. cDNA (2 ml) were used for RT-PCR. qRT-PCR was performed on an ABI Prism 7000 Sequence Detection System (Applied Biosystems) using the Universal Mastermix (Applied Biosystems) with or without addition of SYBR Green. hTERT expression was quantified in real-time with an hTERT-specific FAM-labeled MGB-probe (Applied Biosystems), all other qRT-PCRs were performed with SYBR Green detection. Amplification specificity was verified by melting curve analysis, agarose gel electrophoresis and sequencing of the PCR products. Semiquantitative RTPCRs were performed with the minimal number of reaction cycles necessary to obtain visible PCR products on ethidium bromide-stained agarose gels. 
